BRISTOL-MYERS SQUIBB COMPANY Research and Development in Process
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Research and Development in Process of $0 for the 12-month period ending 2009-12-31, per its 10-K filed 2010-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2011-02-18
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for the quarter ending 2009-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for the quarter ending 2009-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for the quarter ending 2009-06-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for the quarter ending 2009-03-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for fiscal 2009 was $0.00, a 100.00% decline from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for fiscal 2008 was $32.00M, a 86.09% decline from fiscal 2007.
- BRISTOL-MYERS SQUIBB COMPANY research and development in process for fiscal 2007 was $230.00M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-19 | $0.00 derived: sum of 2 quarters · filed 2010-02-19 | $0.00 derived: sum of 3 quarters · filed 2010-02-19 | $0.00 10-K · filed 2010-02-19 |
| 2009-09-30 | $0.00 10-Q · filed 2009-10-22 | $0.00 derived: sum of 2 quarters · filed 2009-10-22 | $0.00 10-Q · filed 2009-10-22 | $0.00 derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | $0.00 10-Q · filed 2009-07-23 | $0.00 10-Q · filed 2009-07-23 | $0.00 derived: sum of 3 quarters · filed 2011-02-18 | $0.00 derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2010-02-19 | $0.00 derived: sum of 2 quarters · filed 2011-02-18 | $0.00 derived: sum of 3 quarters · filed 2011-02-18 | $32.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $0.00 derived: sum of 2 quarters · filed 2011-02-18 | $32.00M derived: sum of 3 quarters · filed 2011-02-18 | $32.00M 10-K · filed 2011-02-18 |
| 2008-09-30 | $0.00 10-Q · filed 2009-10-22 | $32.00M derived: sum of 2 quarters · filed 2009-10-22 | $32.00M 10-Q · filed 2009-10-22 | |
| 2008-06-30 | $32.00M 10-Q · filed 2009-07-23 | $32.00M 10-Q · filed 2009-07-23 | ||
| 2007-12-31 | $230.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |